Advance in chemotherapy-related cognitive dysfunction in breast cancer

Yanmei Zheng,Bin Luo
DOI: https://doi.org/10.3877/cma.j.issn.1674-0785.2015.01.023
2015-01-01
Abstract:Chemotherapy-related cognitive dysfunction (CRCD), which is defined as cognition decline during or after chemotherapy in cancer patients, has attracted more and more attention in the past two decades. As a side effect of chemotherapy, it not only affects the quality of life of the patients, but also hinders them from getting back to their jobs. The overall situation of CRCD in breast cancer patients was reviewed, as well as its advance in mechanism, evaluation method, imaging discovery and treatment. The future direction of this area was also discussed.
What problem does this paper attempt to address?